![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="250" height="148"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
Session 6: Advances for Immunotherapy in Prostate Cancer
12:20 PM – 1:15 PM
Moderator:
Howard Soule, PhD
Prostate Cancer Foundation
Introduction
Howard Soule, PhD
Prostate Cancer Foundation
Clinical Development of PSCA-Targeted CAR T Cells for Advanced Prostate Cancer
Tanya Dorff, MD
City of Hope
Co-expression of a Novel TGFβR Dominant Negative Receptor to Enhance PSMA Chimeric Antigen Receptor Therapy in the Treatment of Castrate Resistant Prostate Cancer Patients
Naomi Haas, MD
University of Pennsylvania